Adverse prognostic factor ID'd in operable breast cancer

Adverse prognostic factor ID'd in operable breast cancer
For women with operable breast cancer, moderate immunohistochemical expression of human epidermal growth factor receptor (HER)-2 (2+) without amplification of HER-2 is an adverse prognostic factor, according to a study published online Sept. 4 in The Oncologist.

(HealthDay)—For women with operable breast cancer, moderate immunohistochemical expression of human epidermal growth factor receptor (HER)-2 (2+) without amplification of HER-2 (HER-2 2+/HER-2) is an adverse prognostic factor, according to a study published online Sept. 4 in The Oncologist.

Valentina Rossi, M.D., from the Institute for Cancer Research and Treatment in Candiolo, Italy, and colleagues compared the clinical outcomes of 1,150 women (median age, 58 years) with operable breast cancer who were not receiving adjuvant . Patients were stratified according to a common HER-2 testing algorithm.

Of the women, 40 percent were considered HER-2 0+; 39 percent were HER-2 1+; 10 percent were HER-2 2+/HER-2; and 11 percent were HER-2+ (3+ or HER-2+) by fluorescence in situ hybridization. The researchers found that, on multivariate analysis, a HER-2 2+/HER-2 status correlated with worse disease-free survival, compared with a HER-2 0 or 1+ status. A HER-2 2+/HER-2 status showed a time-dependent effect on the probability of disease-free survival, with an initial advantage that lessened every year by a factor of 1.649, compared with a HER-2+ status.

"A HER-2 2+/HER-2status is an adverse prognostic factor in patients with operable ," the authors write. "Because of suggestions from randomized trials that the benefits of adjuvant trastuzumab may not be limited to patients with HER-2+ tumors, patients with a HER-2 2+/HER-2status are ideal candidates for studies testing this hypothesis."

One author disclosed financial ties to the pharmaceutical industry.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Putting the brakes on cancer

Dec 19, 2014

A study led by the University of Dundee, in collaboration with researchers at our University, has uncovered an important role played by a tumour suppressor gene, helping scientists to better understand how ...

Peanut component linked to cancer spread

Dec 19, 2014

Scientists at the University of Liverpool have found that a component of peanuts could encourage the spread and survival of cancer cells in the body.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.